HAE · Haemonetics Corporation
$78.78
+3.29% last session
End-of-day data · updated 2026-07-28
Market cap
$4B
Enterprise value
$5B
Trailing P/E
39.0
Forward P/E
14.2
Dividend yield
—
Beta
0.52
Avg volume
1M
Employees
3K
2D change
—
5D change
3.24%
10D change
2.63%
30D change
3.39%
60D change
17.84%
MTD change
6.76%
YTD change
-0.30%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — HAE
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-15
Latest call per bank · past 12 months
Citigroup
Neutral$70.00
-11.1% vs priceBank of America
Buy$80.00
+1.5% vs priceJP Morgan
Neutral$62.00
-21.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-15 | Mizuho | Maintains | Outperform | $85.00 → $90.00 |
| 2026-06-26 | BTIG | Reiterates | Buy | $84.00 |
| 2026-06-17 | BTIG | Reiterates | Buy | $84.00 |
| 2026-06-15 | Mizuho | Maintains | Outperform | $70.00 → $85.00 |
| 2026-05-28 | Citigroup | Maintains | Neutral | $64.00 → $70.00 |
| 2026-05-22 | Bank of America | Upgrade | Neutral → Buy | $72.00 → $80.00 |
| 2026-05-12 | Barrington Research | Maintains | Outperform | $94.00 → $89.00 |
| 2026-05-08 | JP Morgan | Maintains | Neutral | $74.00 → $62.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 70 — overbought territory; the recent run-up may be due for a pause.
- Price vs 50-day MA: Trading 14.0% above the 50-day MA ($72.38).
- Price vs 200-day MA: Trading 23.3% above the 200-day MA ($66.96).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.21) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($47.67) and high ($87.16).
HAE Price Chart
Loading chart for HAE…
Fundamentals
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
More in Medical Devices
ABT
Abbott Laboratories
$182B -15.0% YTD
SYK
Stryker Corporation
$129B -3.7% YTD
MDT
Medtronic plc.
$108B -10.8% YTD
BSX
Boston Scientific Corporation
$68B -52.3% YTD
EW
Edwards Lifesciences Corporatio
$48B -2.6% YTD
GEHC
GE HealthCare Technologies Inc.
$28B -25.4% YTD
DXCM
DexCom, Inc.
$28B 10.5% YTD
PHG
Koninklijke Philips N.V. NY Reg
$24B -4.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.